nach oben

Tumor Biology

Erschienen in:

01.12.2014 | Research Article

Genetic association between cyclin D1 polymorphism and breast cancer susceptibility

verfasst von: XiaoRui Li, XiaoQing Huo, WeiWei Li, QingHui Yang, Ying Wang, XiaoChun Kang

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Cyclin D1 polymorphism has been reported to be associated with risk of breast cancer, but the published studies have yielded controversial results. This study was undertaken to derive a precise risk estimate for the cyclin D1 polymorphism associated with breast cancer risk. We performed a search of EMBASE, PubMed, and Web of Science. In total, data from 18 publications were pooled and the association was assessed by odds ratios (ORs) with 95 % confidence intervals (CIs). This analysis showed that there was no obvious association between the cyclin D1 polymorphism and breast cancer risk in any of the analyzed genetic model. We found the same negative association in stratified analyses by ethnicity, source of controls, and sample size. Our meta-analysis provides an estimate that the presence of cyclin D1 polymorphism may not confer susceptibility to breast cancer.

Ormandy CJ et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78(3):323–35.PubMedCrossRef

Motokura T et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350(6318):512–5.PubMedCrossRef

Knudsen KE et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.PubMedCrossRef

Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol. 1992;8:529–61.PubMedCrossRef

Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther. 2002;1(3):226–31.PubMedCrossRef

Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.PubMedCrossRef

Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002;4(1):14–7.PubMedCrossRef

Ewen ME et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73(3):487–97.PubMedCrossRef

Bala S, Peltomaki P. Cyclin D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042–5.PubMed

10.

Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.PubMedCrossRef

11.

Hou X et al. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol. 2005;82(3):206–9.PubMedCrossRef

12.

Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res. 2006;66(16):8280–6.PubMedCrossRef

13.

Zheng Y et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis. 2001;22(8):1195–9.PubMedCrossRef

14.

Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257–9.PubMed

15.

Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.PubMedCrossRef

16.

Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91–7.PubMed

17.

Onay UV et al. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer. 2008;8:6.PubMedPubMedCentralCrossRef

18.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

19.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

20.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef

21.

Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedPubMedCentralCrossRef

22.

Abramson VG et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 2010;30(4):1279–85.PubMedPubMedCentral

23.

Labonte MJ et al. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(6):1455–64.PubMedCrossRef

24.

Onay VU et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006;6:114.PubMedPubMedCentralCrossRef

25.

Al DA, Qureshi S, Al Saleh KA, Al Qahtani FH, Aleem A, AlSaif A, et al. Studies on the methods of diagnosis and biomarkersused in early detection of breast cancer in the Kingdom of Saudi Arabia: an overview. World J Med Sci. 2013;8(1):36–47.

26.

Krippl P et al. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165–8.PubMedCrossRef

27.

Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917–22.PubMed

28.

Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95–102.PubMedCrossRef

29.

Naidu R, Yip CH, Taib NA. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma. 2008;55(2):87–95.PubMed

30.

Driver KE et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis. 2008;29(2):333–41.PubMedCrossRef

31.

Millar EK et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009;28(15):1812–20.PubMedPubMedCentralCrossRef

32.

Yaylim-Eraltan I et al. Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo. 2009;23(5):767–72.PubMed

33.

Justenhoven C et al. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 2009;124(9):2077–81.PubMedCrossRef

34.

Haiman CA et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the multiethnic cohort. BMC Cancer. 2009;9:43.PubMedPubMedCentralCrossRef

35.

Canbay E et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30(7):3093–8.PubMed

36.

Jelonek K et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51(3):343–52.PubMedCrossRef

37.

Jeon S et al. Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat. 2010;121(3):737–42.PubMedCrossRef

38.

Absenger, G., et al. (2013). A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog.

39.

Bedewy AM et al. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON. 2013;18(1):227–38.PubMed

40.

Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15(6):718–27.PubMedCrossRef

41.

Simpson JF et al. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997;151(1):161–8.PubMedPubMedCentral

42.

Gillett CE et al. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol. 1998;184(4):396–400.PubMedCrossRef

43.

Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.PubMed

44.

Wu J et al. Identification of the cyclin D1b mRNA variant in mouse. Mol Biol Rep. 2009;36(5):953–7.PubMedCrossRef

45.

Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.PubMed

46.

Pabalan N et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2773–81.PubMedCrossRef

47.

Lu C et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):571–5.PubMedCrossRef

48.

Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63.PubMedCrossRef

49.

Cui J, Shen L, Wang Y. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev. 2012;13(10):5023–5.PubMedCrossRef

50.

Yang J et al. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects. Oncol Res. 2011;19(12):519–25.PubMedCrossRef

Titel: Genetic association between cyclin D1 polymorphism and breast cancer susceptibility
verfasst von: XiaoRui Li
XiaoQing Huo
WeiWei Li
QingHui Yang
Ying Wang
XiaoChun Kang
Publikationsdatum: 01.12.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2489-5

Springer Medizin

Genetic association between cyclin D1 polymorphism and breast cancer susceptibility

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes

CD109 is a potential target for triple-negative breast cancer

Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis

Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma

Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data

MicroRNA-191 promotes pancreatic cancer progression by targeting USP10

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie